25E-NBOH Blotter

25E-NBOH

4-Ethyl-2,5-dimethoxy-(N-(2-hydroxybenzyl))phenethylamine (also known as 25E-NBOH and 2C-E-NBOH) is a closely related analog of 25E-NBOMe. 25E-NBOH is a synthetic psychedelic substance of the phenethylamine chemical class and is reported to share most of its properties with the exception of a moderately reduced potency and a shorter duration with 25E-NBOMe. Phenethylamine's produce an array of visually-dominant and stimulating psychedelic effects when administered.

25E-NBOH is a derivative of the hallucinogen 2C-E. It was first developed by Martin Hansen at the University of Copenhagen in 2010 as a brain imaging agent, but has subsequently been sold as a designer drug, first being identified in Brazil in 2018 on seized blotter paper, as well as in several European countries.[4] Although it is unknown exactly how 25E-NBOH exerts its effects it is believed to act by binding to serotonin receptors in the brain. Related substances of the NBOH family include: 25B, 25C, and 25I, all of which were identified in 2016 by the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA).

Similar to other known psychedelics, compounds of the NBOH family are not orally active and should be administered sublingually by placing and holding it in one's mouth and allowing it to absorb over a period of 15-25 minutes.

Subjective effects include open and closed-eye visuals, time distortion, enhanced introspection, ego loss, stimulation, and euphoria. User reports characterize 25E-NBOH as a clear headed, dose-sensitive psychedelic that is capable of producing strong visual distortions along with a significant "body load". 25E's body load manifests itself through vasoconstriction. Users describe the body load as making their muscles very sore and many take supplements to counteract these effects. 

https://psychonautwiki.org/wiki/25E-NBOH